Chemokine receptors have been targeted in therapeutic strategies, and recent years have seen promising results from CCL2/CCR2 antagonists in treating inflammatory and fibrotic diseases (29) and cancer immunotherapy (30, 31). Here, CCL2 is linked to cancer.